One Drop announced today that new peer-reviewed research demonstrates sustained blood glucose reductions with its diabetes platform.
New York-based One Drop presented the clinical health outcomes associated with the long-term use of its digital diabetes offering at the Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Barcelona. The results demonstrated clinically sustained and statistically significant reductions in average blood glucose beyond six months and one year, reflecting meaningful reductions in estimated A1C.
Get the full story at our sister site, Drug Delivery Business News.